GW Parma’s Sativex Launched in UK
This week Sativex was given a green signal by the UK authorities. Sativex is a medicine used for the cure of Multiple Sclerosis. It is a cannabis-based medicine, which is available in the form of a mouth spray.
The drug was launched on Monday in the UK and will be sold by Bayer.
It is being produced by GW Pharmaceuticals. Chief Executive of the Company, Dr. Geoffrey Guy reveals that it is the first cannabis based medicine, which has been given consent by having a full pharmaceutical process at anyplace in the world. This drug is also the first plant based medicine, which has been given a nod in the recent times.
Dr. Guy also revealed that the Company has launched its first such range of products comprising of cannabis plant.
Sativex is sprayed under the tongue and is similar in volume to an asthma inhaler. One mouth spray can give 90 sprays. A patient of Multiple Sclerosis administers around eight sprays a day.
Patients in UK had an access to the drug since 2005, but on a "named patient" basis, in which they had to ask the manufacturer for supply of the drug. Now, the drug will be available across the country.
New Zealand News
- Tesla offering new discounts & perks in China amid negative press
- Electric Vehicle Council slams Victoria Government for proposed punitive mileage tax on electric cars
- Chinese EV brand Ora unveils VW Beetle-inspired electric car Punk Cat
- Swapping personal car for e-bicycle saved over $50,000 in just 7 years: San Francisco woman
- Hyundai Motor Corp to create ultra-fast EV charging network E-pit in Korea
- Tesla pockets roughly $101 million in profit from sale of some of its bitcoins
- Norway’s ICE car sales decline as buyers making shift to EVs
- Pursang launches Retro-inspired E-Track Motorcycle for Euro 14,449 in Netherlands
- ElectReon successfully tests dynamic wireless EV charging system on public road in Sweden